Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy

European Journal of Haematology

Volumn 75, Issue 2, 2005, Pages 116-123

  Doorduijn, Jeanette ^a   Buijt, Ivonne ^a   Van Der Holt, Bronno ^a   Steijaert, Monique ^a   Uyl De Groot, Carin ^a   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CHOP; Elderly; G CSF; NHL; Qality of life; Randomized controlled trial

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

AGED; AGGRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; PREDNISONE; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; VINCRISTINE;

EID: 22444443711     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00438.x     Document Type: Article

References (19)

1. TCHEN N, SOUBEYRAN P, EGHBALI H, et al. Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients. Crit Rev Oncol Hematol 2002;43:219-226.
2. FISHER RI, GAYNOR ER, DAHLBERG S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
3. SONNEVELD P, DE RIDDER M, VAN DER LELIE H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539.
4. COIFFIER B, LEPAGE E, BRIERE J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
5. OSBY E, HAGBERG H, KVALOY S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840-3848.
6. ZINZANI PL, PAVONE E, STORTI S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non- Hodgkin's lymphoma. Blood 1997;89:3974-3979.
7. DOORDUIJN JK, VAN DER HOLT B, VAN IMHOFF GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-3050.
8. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
9. DOLAN P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.
10. AARONSON NK, AHMEDZAI S, BERGMAN B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
11. SMETS EM, GARSSEN B, BONKE B, DE HAES JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-325.
12. SMETS EM, GARSSEN B, CULL A, DE HAES JC. Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. Br J Cancer 1996;73:241-245.
13. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
14. WISLOFF F, EIKA S, HIPPE E, et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996;92:604-613.
15. HJERMSTAD MJ, FAYERS PM, BJORDAL K, KAASA S. Using reference data on quality of life-the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 1998;34:1381-1389.
16. OSOBA D, RODRIGUES G, MYLES J, ZEE B, PATER J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144.
17. KAASA S, HJERMSTAD MJ, JORDHOY MS, WISLOFF F, LOGE JH. Compliance in quality of life data: a Norwegian experience. Stat Med 1998;17:623-632.
18. JERKEMAN M, ANDERSON H, CAVALLIN-STAHL E, et al. CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial. Ann Oncol 1999;10:1079-1086.
19. PFREUNDSCHUH M, TRUMPER L, KLOESS M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-641.